朱朱胺A对虫疾病中氨基酸神经递质配置的调节作用
Fei Fan1, Si Zhang1,2, Hongwei Wu3
1Department of Paediatrics, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Brain and behavior
|November 12, 2025
概括
朱化A (JuA) 通过平衡大脑化学物质谷氨酸和GABA来帮助滴答障碍 (TD) 的老鼠. 将JuA与Tiapride结合使用,为治疗TD提供了更好的结果.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 生物化学 生化学
背景情况:
- 障碍 (TD) 的特征是神经递质水平发生变化,特别是谷氨酸 (Glu) 和胺黄油酸 (GABA).
- 柔化物A (JuA) 是一种天然化合物,在调节神经功能方面表现出潜力.
- 了解TD中JuA的具体机制对于开发有效治疗方法至关重要.
研究的目的:
- 为了研究JuA对Glu和GABA水平在尾状膜 (CPu) 的影响,Tic障碍 (TD) 的老鼠模型.
- 为了比较单独使用JuA与与Tiapride结合使用JuA治疗TD的疗效.
- 探索谷氨酸转运体 (GLT-1和GLAST) 在JuA的作用机制中的作用.
主要方法:
- 使用腹腔内注射伊米诺迪普罗皮奥尼特里尔 (IDPN) 制订了一种小鼠图克障碍 (TD) 模型.
- 微透析和高性能液态染色学 (HPLC) 用于测量尾状膜 (CPu) 中的细胞外Glu和GABA水平.
- 对GLT-1和GLAST蛋白质的表达进行了刻板的行为评分和免疫组织化学.
主要成果:
- TD老鼠表现出Glu增加,GABA降低,并提高了刻板印象行为得分.
- 两种JuA和Tiapride治疗都显著使Glu和GABA水平正常化,并减少了行为症状.
- 与单一治疗相比,JuA和Tiapride的组合显示出更好的治疗效果,可能是通过升调GLT-1和GLAST.
结论:
- 朱胺A (JuA) 通过调节尾状膜中的谷氨酸和GABA水平,有效地改善了老鼠的滴滴障碍 (TD) 症状.
- 朱亚的治疗效益可能与谷氨酸转运体GLT-1和GLAST的上调有关.
- 使用JuA和Tiapride的组合疗法为提克障碍治疗提供了一个有希望的,增强的治疗策略.
相关概念视频
Drugs Affecting Neurotransmitter Release or Uptake
1.5K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.5K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
802
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
802
Drugs Affecting Neurotransmitter Synthesis
2.1K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.1K
Anxiolytic Drugs: Overview
1.0K
Anxiolytic drugs are vital in managing anxiety disorders by effectively alleviating symptoms such as excessive fear, tachycardia, and tremors. There are several classes of anxiolytic medications, each with unique mechanisms of action and potential side effects.
Primary Types of Anxiolytic Drugs
1. Benzodiazepines:
Benzodiazepines bind to the GABA-A receptor in the brain, enhancing GABA's interaction. This action reduces neurotransmission, effectively blocking anxiety-associated limbic...
Primary Types of Anxiolytic Drugs
1. Benzodiazepines:
Benzodiazepines bind to the GABA-A receptor in the brain, enhancing GABA's interaction. This action reduces neurotransmission, effectively blocking anxiety-associated limbic...
1.0K
Excitatory and Inhibitory Effects of Neurotransmitters
12.5K
When an action potential reaches the presynaptic axon terminal, it releases neurotransmitters from the neuron into the synaptic cleft at a chemical synapse. The released neurotransmitter can be excitatory or inhibitory. The critical criteria commonly used to determine whether a molecule is a neurotransmitter at a chemical synapse are the molecule's presence in the presynaptic neuron. Second, its release is in response to strong presynaptic depolarization. And lastly, the presence of...
12.5K
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
1.2K
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
1.2K


